duvelisib (Copiktra)
Jump to navigation
Jump to search
Indications
Adverse effects
- increased serum AST, serum ALT
- pneumonitis
- dermatitis
- enteritis/colitis
- may increase risk of death[2]
Mechanism of action
- dual PI3K inhibitor
- inbibits PI3K-delta & PI3K-gamma
More general terms
References
- ↑ Ingram I Duvelisib OK'd for Three Blood Cancers Drug will need to separate itself from previous PI3K inhibitor. MedPage Today. September 24, 2018 https://www.medpagetoday.com/hematologyoncology/leukemia/75292
- ↑ 2.0 2.1 Worcester S FDA Warns of Increased Risk of Death With CLL, Lymphoma Drug. Medscape. June 30, 2022 https://www.medscape.com/viewarticle/976447